How Much Does GLP-1 Cost?

Summary: Brand-name GLP-1 medications list at roughly $968 to $1,349 per month before any discount, but manufacturer self-pay programs from Lilly and Novo Nordisk have pulled real cash prices down to $349 to $499 for most patients who pay direct.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: a brand-name GLP-1 lists at $968 to $1,349 per month in the United States. Almost nobody pays that. With a commercial insurance plan that covers the drug, your copay typically runs $25 to $150. With no insurance, manufacturer self-pay programs from Eli Lilly and Novo Nordisk now sell vials direct for $349 to $499 per month. Compounded GLP-1s, which exploded during the 2023 to 2025 shortage, still exist for $149 to $400 per month, but the legal landscape has shifted hard since the FDA declared the shortages resolved.

This page walks the actual numbers for every path, with sources.

List prices for brand-name GLP-1s in 2026

Manufacturer list price, also called wholesale acquisition cost, is the sticker. It is the number insurers negotiate down from and the number a pharmacy will quote you if you walk in with no coverage and no discount card.

These numbers come straight from manufacturer pricing pages and wholesale price databases. Wegovy and Saxenda hold the top of the range at $1,349 because Novo Nordisk has held that price steady since launch. Ozempic, the cheapest of the Novo lineup, sits just under a thousand. Lilly's tirzepatide products run a tight $1,069 to $1,086 band.

What you actually pay with commercial insurance

If your employer-sponsored or marketplace plan covers the drug on its formulary, your monthly out-of-pocket cost falls somewhere between $25 and $150 in most plans. The exact number depends on three things: the formulary tier, whether prior authorization is required, and whether you have hit your annual deductible.

Tier 2 (preferred brand) generic-style copays usually land at $25 to $50. Tier 3 (non-preferred brand) copays run $50 to $150. Tier 4 (specialty) can be coinsurance rather than a flat copay, meaning you pay 25 to 50 percent of the negotiated price, which on a $900 negotiated rate is $225 to $450 per month.

Coverage for the diabetes indications is widespread. Coverage for weight loss indications is uneven. A 2025 KFF analysis found roughly 57 percent of large-employer plans covered GLP-1s for diabetes; only about 25 percent covered them for obesity, and most of those required prior authorization, a BMI cutoff above 30, or documentation of failed lifestyle intervention.

Add in the manufacturer copay savings card, and even covered patients can drop their out-of-pocket cost further. Lilly's Zepbound savings card brings the monthly copay to as little as $25 for commercially insured patients. Novo Nordisk's Wegovy and Ozempic cards do the same.

Manufacturer self-pay programs

This is where the GLP-1 cost story changed in 2024 and 2025. Lilly and Novo Nordisk both launched direct-to-patient cash channels that bypass the insurance system, with prices dramatically below list.

LillyDirect for Zepbound

Lilly sells Zepbound in single-dose vials, not pens, through LillyDirect Pharmacy. As of the most recent price update, the self-pay tiers are:

• 2.5 mg vial: $349 per month for new starters
• 5 mg vial: $499 per month
• 7.5 mg vial: $599 per month
• 10 mg vial: $699 per month
• 12.5 mg vial: $799 per month
• 15 mg vial: $899 per month ^[1]

These prices require a valid prescription and direct shipment from the LillyDirect pharmacy. They are cash-pay only and cannot be combined with insurance. The vials replicate the pen formulation; the only difference is you draw the dose with a separate syringe instead of clicking a pen.

Mounjaro is not offered through this self-pay channel. Diabetes patients buying Mounjaro still pay list price or go through their pharmacy benefit.

NovoCare for Wegovy and Ozempic

Novo Nordisk runs NovoCare Pharmacy, its direct-ship program for self-pay patients ^[2]. The flagship offering is Wegovy at $499 per month for any maintenance dose, with a $199 first-month starter pack for new patients. Ozempic is also available at a self-pay rate that lands close to $499, depending on dose and any current promotion.

Both Lilly and Novo programs require you to either lack insurance coverage for the drug or actively choose not to use it. Both ship from their own mail-order pharmacies. Both are aimed at the same market: the patient whose insurance refuses to cover GLP-1s for weight loss but who can swing $500 a month in cash.

What this means in practice

A patient who five years ago had two choices, $1,349 list or nothing, now has a third option at $349 to $499 from the manufacturer. The gap between insurance copay and manufacturer self-pay has narrowed from 50x to roughly 4x. For households earning above the Medicaid line but without comprehensive obesity coverage, this is the path most people end up on.

Medicare and Medicaid

Medicare coverage of GLP-1s for weight loss is narrow. Federal law specifically excludes Medicare Part D from covering drugs used for weight loss ^[4]. That exclusion has carved out a strange patchwork:

• Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus: covered by most Medicare Part D plans for type 2 diabetes, with copays ranging from $0 (extra-help recipients) to several hundred dollars in the deductible phase or coverage gap.
• Wegovy: covered by Medicare Part D since March 2024 only when prescribed for cardiovascular risk reduction in patients with established heart disease and obesity, following the SELECT trial label expansion. Not covered when the prescription is for weight loss alone.
• Zepbound: covered by Medicare Part D since late 2024 for the moderate-to-severe obstructive sleep apnea indication, following Lilly's OSA label expansion. Not covered for weight loss alone.
• Saxenda: not covered by Medicare. Indicated only for weight management.

CMS proposed in late 2024 to broaden Medicare coverage to GLP-1s for obesity treatment starting January 2027, but that proposal sits in regulatory review. As of mid-2026, the weight-loss-only path through Medicare remains blocked unless one of the cardiovascular or OSA carve-outs applies.

Medicaid coverage varies wildly by state. About a dozen states cover GLP-1s for weight loss; the rest cover only the diabetes indications. Some states require BMI documentation, prior failed therapy, or step-edits before approving.

Compounded GLP-1s after the shortage

From mid-2022 through late 2024, the FDA listed both semaglutide and tirzepatide as in shortage. Under section 503A and 503B of the federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce versions of a drug while it is on the shortage list. This created a $200-to-$400-per-month compounded GLP-1 market that served hundreds of thousands of patients during the brand-name supply crunch.

The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025 ^[3]. That removed the legal basis for mass-production 503B compounding of either drug. Compounding pharmacies received wind-down deadlines: 503A facilities until April 22, 2025 for tirzepatide and May 22, 2025 for semaglutide, with 503B outsourcing facilities given additional time.

What remains in 2026 is a narrower compounded market. Pharmacies can still legally produce patient-specific compounded versions if a prescriber documents a clinical need not met by the FDA-approved product, for example a documented allergy to an excipient in the brand formulation or a dose strength not commercially available. Marketing-driven mass compounding is no longer permitted.

Cash prices for compounded GLP-1s, where they are still legally dispensed, run roughly:

The price drop people experienced in 2023 from compounded sources, sometimes as low as $99 for a research-grade semaglutide vial, has largely closed. Patients still on compounded therapy who started during the shortage face a decision: switch to a brand at the manufacturer's $499 self-pay rate, or work with their prescriber to document a clinical reason to continue compounded.

Annual cost: what a year of GLP-1 therapy actually runs

These figures assume continuous monthly use. Real-world adherence data shows roughly half of patients who start a GLP-1 for weight loss discontinue within 12 months, usually because of cost, side effects, or both. If you stop, the weight typically returns. That is the practical math behind why coverage decisions matter so much: this is a chronic medication, and the annual cost compounds year over year for as long as you stay on it.

Cost per pound lost

A rough back-of-envelope: in the SURMOUNT-1 trial, Zepbound at the 15 mg dose produced about 50 pounds of weight loss over 72 weeks. At the self-pay rate of $899 a month for the 15 mg vial, that is roughly $15,500 over the trial period, or about $310 per pound lost. At insurance copay rates of $25 a month, the same trajectory costs about $430 total, or under $9 per pound. The variance is two orders of magnitude, driven entirely by coverage status.

Wegovy at the 2.4 mg dose in STEP-1 produced about 35 pounds of loss over 68 weeks. At NovoCare self-pay rates of $499 a month, that is about $7,800 over the trial period, or $223 per pound. At list price the same loss costs $22,000, or $629 per pound.

These are blunt averages and they say nothing about what an individual patient will respond to or for how long.

How to lower your GLP-1 cost

The decision tree most patients walk through, in rough order of best to worst financial outcome:

1. Check whether your commercial insurance covers the drug. Call the number on the back of the card and ask whether semaglutide, tirzepatide, or your specific brand is on the formulary and what the copay is. Ask whether prior authorization is required.
2. If covered, ask whether the manufacturer copay card applies on top. Lilly's and Novo's cards can drop a $150 copay to $25.
3. If not covered, check the manufacturer self-pay program. LillyDirect for Zepbound, NovoCare for Wegovy or Ozempic. These are the most reliable cash channels at $349 to $499 per month.
4. If even self-pay is out of reach, check patient assistance. Both Lilly Cares Foundation and Novo Nordisk Patient Assistance Program provide free or reduced-cost medication to patients below specific income thresholds, usually around 400 percent of the federal poverty line.
5. If a clinical reason exists to use a compounded formulation (specific allergy, dose strength), work with a prescriber and a 503A pharmacy.

A common mistake is to chase the lowest sticker price through unverified online sellers and end up with product of unknown quality. The manufacturer self-pay programs at $499 are the floor for legitimate, FDA-approved GLP-1 medication for cash payers in 2026.

Why GLP-1s cost what they do

The list prices look high because they are. US prescription drugs in general carry list prices several times what the same medications sell for in Europe or Canada. Wegovy in Denmark sells for roughly $185 per month. Ozempic in the UK runs about $80 per month. The same molecule in the US lists at over $1,000. The price difference reflects the US drug pricing system, not the cost of manufacture.

Net prices, the figure manufacturers actually realize after rebates to pharmacy benefit managers, are 40 to 60 percent below list for GLP-1s ^[5]. That means Novo Nordisk receives roughly $400 to $700 per Wegovy prescription on average, not the $1,349 list. The rebate flows back to the PBM and then partially to the insurance plan. The patient sees the list price reflected in their deductible or coinsurance calculations.

The introduction of self-pay programs at $349 to $499 reveals what the manufacturers consider acceptable margin without an insurer in the middle. That floor is where the cash market is settling.

Common questions about GLP-1 cost

How much does GLP-1 cost per month without insurance in 2026?

Brand-name list prices run $968 to $1,349 per month. Through manufacturer self-pay programs like LillyDirect and NovoCare, the same products are available at $349 to $499 per month.

How much do weight loss injections cost out of pocket?

Out-of-pocket, expect $25 to $150 with insurance coverage, $349 to $499 through manufacturer self-pay vials, or $149 to $500 for compounded versions where still legally dispensed.

What is the lowest cost GLP-1 option in 2026?

Legitimately, compounded semaglutide from a licensed 503A pharmacy with valid clinical justification runs around $149 to $250 per month. Among brand-name products, Zepbound 2.5 mg vials through LillyDirect at $349 are the lowest self-pay tier.

Does Medicare cover GLP-1 for weight loss?

No. Medicare Part D is statutorily barred from covering drugs used for weight loss. It covers GLP-1s for type 2 diabetes, and it covers Wegovy specifically for cardiovascular risk reduction in patients with established heart disease and Zepbound for obstructive sleep apnea.

How much does Wegovy cost per month?

Wegovy lists at $1,349 per month. With commercial insurance the copay is usually $25 to $150. Through NovoCare self-pay it is $499 per month, with a $199 first-month introductory rate for new patients.

How much does Zepbound cost per month?

Zepbound pens list at $1,086 per month. With insurance the copay is typically $25 to $150. Through LillyDirect, single-dose vials run $349 for the 2.5 mg starter and $499 for the 5 mg dose, scaling up to $899 for 15 mg.

How much does Ozempic cost without insurance?

List price for Ozempic is $968.52 per month. Novo Nordisk's NovoCare program offers a self-pay rate close to $499 per month for eligible patients.

What is the annual cost of GLP-1 maintenance therapy?

At list price, $11,616 to $16,188 per year. With insurance coverage, $300 to $1,800. Through manufacturer self-pay, roughly $4,200 to $10,800. Most people who start a GLP-1 stay on it long-term to maintain weight loss, so the annual figure compounds year over year.

Why is the cost so different between insurance and cash?

List prices include rebates that flow back to pharmacy benefit managers and insurance plans. Manufacturer self-pay programs bypass the rebate system entirely, selling at the net price the manufacturer would otherwise realize after PBM negotiation.

Can I get GLP-1 for free?

Lilly Cares Foundation and Novo Nordisk Patient Assistance Program provide free medication to patients below specific income thresholds, typically around 400 percent of the federal poverty line, who lack insurance coverage for the drug.

What this article does not cover

This is the class-wide cost overview. Drug-specific cost pages, side effect and tolerability articles, and the comparison between semaglutide and tirzepatide live on dedicated pages. State-specific telehealth pricing and pharmacy formulary specifics also have their own breakdowns. The numbers here are the national picture as of mid-2026; check the manufacturer pages cited above for the current month's quoted prices, since both Lilly and Novo adjust the self-pay tiers periodically.